Review Article

Pathological and radiological approach to the small airway disease in asthma: Limitation of current inhaled corticosteroid therapy

Hiroshi Tanaka, Midori Hashimoto, Shin Sahara, Tetsuro Ohnishi, Masaru Fujii, Kazuhiko Suzuki, Toyohiro Saikai and Shosaku Abe

Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan

ABSTRACT

The small airway disease in asthma is characterized by airway wall thickening associated with eosinophilic inflammation and hypervascularity. In our study, predicted forced expiratory volume in 1 s (% FEV₁) correlated with the vascularity in the inner layers of large airways but not for small airways. High-resolution computed tomography (CT) scans of 0.5 mm collimation during acute mild exacerbations revealed mucus plugging, air-space nodules and ground-glass opacities. Mean lung density on CT in acute exacerbations was significantly increased compared with that in remission. These results suggest that the involvement of the small airways and lung parenchyma would be increased during exacerbations. Pathologically, eosinophils were significantly reduced by treatment with chlorofluorocarbon–beclomethasone dipropionate (BDP) in the large airways, but not in the small airways. New fine-particle inhaled corticosteroids (ICS), such as hydrofluoroalkane–BDP, can reach the small airways and lung parenchyma in asthmatic patients. From the results of peak inspiratory flow (PIF) through each dry powder inhaler in Japanese people, measurement of PIF should be recommended before the use of dry powder inhaler. In the present review, we address small airway disease in asthmatic patients using pathological and radiological methods and discuss the critical problems of current ICS therapy.

Key words: asthma, eosinophil, high-resolution computed tomography, inhaled corticosteroid, small airway.

INTRODUCTION

Asthma is a chronic inflammatory disease affecting the whole bronchial tree, from large to small airways. However, information about the small airways and lung parenchyma in asthmatic patients and comparison of bronchial remodeling and inflammation between central and peripheral airways is lacking. The contribution of small airway involvement to acute exacerbations of asthma also remains unknown. High-resolution computed tomography (HRCT) has been useful for assessing structural changes in the asthmatic lung and permits investigation of the relationship between airway wall thickening and clinical parameters. Multidetector-row CT (MDCT) is now widely available and can scan the whole lung within a very short time compared with previous HRCT, enabling us to evaluate acute exacerbations with mild respiratory failure.

Inhaled corticosteroid (ICS) is a well-established anti-inflammatory therapy for asthma and steroid receptors are located throughout the bronchial tree. In general, the smaller particles can reach the more peripheral airways but, for an optimal therapeutic response to ICS, the inhaled particles should reach both large and small airways. Recently, a solution steroid aerosol, hydrofluoroalkane–beclomethasone dipropionate (HFA-BDP), was developed with a mass median aerodynamic diameter (MMAD) of 1.1 µm, raising the possibility that this extra-fine ICS may be more effective than...
conventional chlorofluorocarbon (CFC)-BDP, with an MMAD of 3.5 µm, in improving function in the small airways of asthmatic patients through more effective suppression of peripheral airway inflammation. We also address the problems regarding inhalation technique in patients with asthma and chronic obstructive pulmonary disease (COPD) and the significance of particle size of dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) of ICS. In the present review, we address small airway disease in asthmatic patients using pathological and radiological methods and discuss the critical problems of current ICS therapy.

**PATHOLOGICAL APPROACH**

**Bronchial wall inflammation**

Many investigators have reported inflammatory changes in the small airways in subjects with fatal and mild asthma using lung specimens obtained by operation. Saetta et al. found evidence of increased mucus plugging, airway smooth muscle thickening and infiltration of inflammatory cells, including eosinophils, in the small airways in fatal asthma. Kuwano et al. and Carroll et al. reported that remodeling also occurred in mild asthma. Hamid et al. observed that inflammatory changes were more severe in small airways than in large airways of asthmatic patients who had undergone lung resection for tumor, whereas Kraft et al. reported that eosinophilic inflammation was greater in peripheral tissue than in the large bronchi in the early morning hours.

**Bronchial wall angiogenesis**

Angiogenesis is characteristic of airway remodeling in asthma, but there have been few reports as to bronchial wall hypervascularity in the small airways. We found that the number of vessels and percent vascularity were increased in both large and small airways in patients with asthma compared with control subjects. Because previous in vivo quantitative studies used biopsy specimens obtained by fiberoptic bronchoscopy, the observations were limited to the large airways, whereas our data extend the finding of increased vascularity to small airways. Li et al. did not find any relationship between clinical parameters and airway vascularity in patients with mild and moderate asthma, although Salvato and Vrugt et al. showed that subjects with severe asthma had more vessels compared with mild to moderate asthmatics. In contrast, vascularity is more prominent in the inner area, suggesting that airway edema due to plasma leakage from mucosal capillary vessels may increase the narrowing of the bronchial lumen and increase airway resistance. Our study showed that percentage forced expiratory volume in 1 s (%FEV_1) correlated with vascularity in the inner layer of the large airways, but not in the small airways. These results suggest that hypervascularity of the inner layer of large airways may contribute not only to disease severity, but also to airflow limitation in asthmatic patients.

**RADILOGICAL APPROACH**

**High-resolution CT appearance at asthma exacerbation**

High-resolution CT is one of the most useful tools for imaging the small airways and the direct signs are the result of changes in the airway wall or lumen. Teel et al. summarized small airway abnormalities as tubular, nodular or branching linear structures on HRCT scans and described indirect signs of small airway disease resulting from changes in the lung parenchyma distal to the diseased small airway due to air trapping, subsegmental atelectasis, centrilobular emphysema and air-space nodules. Niimi et al. reported that airway wall thickening measured by CT appeared in all degrees of asthma disease and suggested its magnitude may relate to the duration and degree of airflow limitation. To evaluate airway remodeling of the large and small airways and lung parenchyma during mild asthma exacerbations, we assessed the CT findings of the right upper lobe taken at 0.5 mm intervals and 0.5 mm collimation using MDCT. We examined the bronchial wall of generations 2–5 in stable asthmatic patients and patients with a mild exacerbation. We found that an increase of wall area of generation 4 bronchus was most responsible for airflow limitation (%FEV_1) in stable asthma, but found no relationship during mild exacerbation, suggesting that, during asthma exacerbation, airflow may be restricted not only by large airway narrowing and inflammation, but also by obstruction of the small airway by mucus plugging. Actually, air-space nodules and ground-glass opacities (GGO) appeared on 0.5 mm collimation HRCT during mild exacerbation (Fig. 1a,b). Micronodules also existed at the end of the bronchus and continued to the pulmonary artery, findings that appear in case of diffuse panbronchiolitis,
which suggest that these nodules may reflect small airway wall inflammation and mucus plugging. Ground-glass opacities during asthma exacerbation suggest eosinophil-dominant inflammation in the lung parenchyma.

High-resolution CT lung density

The low-attenuation area (LAA) on CT has been shown to represent macroscopic or microscopic emphysema in patients with COPD and also has been used in the detection of airspace enlargement in patients with asthma. Mitsunobu et al.\textsuperscript{17} reported that LAA in non-smoking asthmatics (11.0% ± 9.7) was significantly increased compared with that in non-smoking controls (3.6% ± 3.2) and mean lung density (MLD) in non-smoking asthmatics (–845 ± 32 Hounsfie ld units (HU)) was significantly lower than that in non-smoking controls (–818 ± 29 HU). Mitsunobu et al.\textsuperscript{17} also reported that both MLD and LAA correlated with parameters of airflow limitation and lung volume, but not with the lung transfer factor in non-smoking asthmatic patients.\textsuperscript{18} We also measured CT lung density using MDCT in patients with stable asthma and with a mild exacerbation.\textsuperscript{19} In our study, LAA in non-smoking asthma (10.3 ± 5.4%) was increased, but not significantly, compared with non-smoking controls (9.2 ± 4.2%) and MLD in non-smoking asthma (–871 ± 31 HU) was higher, but not significantly, compared with non-smoking controls (–861 ± 31 HU). The different results may be explained by the selection of patients, because we excluded subjects with emphysematous change, giant bulla or cystic lesions on CT,\textsuperscript{19} but Mitsunobu et al.\textsuperscript{17,18} did not. We also found that MLD in patients with mild exacerbations was significantly higher than in patients with stable asthma, whereas the LAA area in patients with mild exacerbation was significantly decreased compared with that in patients with stable asthma (S Sahara et al., unpubl. obs., 2003). These results suggest that peripheral lung lesions may develop during asthma exacerbations. There has been no report about CT lung density during asthma exacerbation, but Kraft et al.\textsuperscript{20} reported that lung biopsy specimens at 04.00 h in patients with nocturnal asthma demonstrated increased eosinophil infiltration into the lung parenchyma. We speculate that lung parenchyma lesions may be increased during asthma exacerbations.

The difference in peripheral lung density between inspiratory and expiratory CT is also useful for the detection of air trapping by small airway narrowing. Goldin et al.\textsuperscript{21} evaluated the efficacy of inhaled broncho-constrictor (methacholine) and bronchodilator (albuterol) by assessing expiratory CT (at the residual volume level). They observed that the marked increase in LAA due to air trapping by inhalation of methacholine returned to baseline levels after inhalation of albuterol, suggesting that LAA on inspiratory CT reflects prompt changes of small airway obstruction in asthmatic patients.

LIMITATION OF ICS THERAPY

Lung deposition of ICS

Inhaled corticosteroids are powerful anti-inflammatory drugs and, for optimal therapeutic response with ICS, the inhaled particles should reach both the large and small airways. Recently, a fine-particle ICS of HFA-BDP has become available with an MMAD of 1.1 µm.\textsuperscript{5} Leach et al.\textsuperscript{22} reported that lung deposition, using gamma scintigraphy was greater with HFA-BDP (53%) compared with CFC-BDP (4%) in nine healthy non-smoking volunteers and that HFA-BDP was distributed diffusely throughout the lungs, whereas deposition of CFC-BDP was mainly in the large and intermediate airways. The pattern of lung deposition showed that HFA-BDP was spread diffusely through the lung airways, whereas CFC-BDP was confined to the large airways with little in the small airways. We evaluated lung specimens of mild and moderate asthma obtained at operation due to a small lung cancer\textsuperscript{10} and the number of eosinophils in the bronchial wall was significantly reduced by CFC-BDP 400–600 µg/day in the large airways, but not in the
small airways (Fig. 2). Possibly, the particle size of CFC-BDP (MMAD 3.5 µm) prevented it reaching to the small airways.

**Peak inspiratory flow in DPI**

Three devices of DPI, namely Diskhaler®, Diskus® (GlaxoSmithkline, Brentford, UK) and Turbuhaler® (AstraZeneca, Lund, Sweden), are currently available in Japan. They are increasingly being used in preference to

![Fig. 2 Number of eosinophils at the inner layer of large airways (inner diameter 2–5 mm) and small airways (inner diameter < 2 mm) in lung specimens obtained by operation due to a peripheral small malignant tumor. In the large airways, the number of eosinophils in patients treated with chlorofluorocarbon–beclomethasone dipropionate (CFC-BDP) was significantly \( P = 0.013 \) decreased compared with subjects without CFC-BDP treatment; however, this sort of reduction in eosinophil numbers was not seen in the small airways.](image)

**Table 1 Patient characteristics**

<table>
<thead>
<tr>
<th></th>
<th>Asthma</th>
<th>COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. patients</td>
<td>223</td>
<td>43</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>90/133</td>
<td>38/5</td>
</tr>
<tr>
<td>Age (years)</td>
<td>53 ± 16</td>
<td>71 ± 8</td>
</tr>
<tr>
<td>PEF (L/min)</td>
<td>361 ± 121</td>
<td>225 ± 101</td>
</tr>
<tr>
<td>PIF (L/min)</td>
<td>230 ± 73</td>
<td>165 ± 65</td>
</tr>
<tr>
<td>Inhaled corticosteroids (no. patients)</td>
<td>CFC-BDP: 95, DPI-FP (diskhaler): 106, None: 22</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>

Where appropriate, data are given as the mean ± SD.

COPD, chronic obstructive pulmonary disease; PEF, peak expiratory flow; PIF, peak inspiratory flow; CFC, chlorofluorocarbon; BDP, beclomethasone dipropionate; DPI, dry powder inhaler; FP, fluticasone.

![Fig. 3 Correlation between peak expiratory flow (PEF) and peak inspiratory flow (PIF) measured using In-Check® (Clement Clarke, Harlow, Essex, UK) in patients with asthma (λ; \( n = 223; r = 0.67; P < 0.0001 \)) and chronic obstructive pulmonary disease (COPD; δ; \( n = 43; r = 0.69; P < 0.0001 \)). The PIF in COPD is relatively higher than that in asthma compared with the value of PEF.](image)

![Fig. 4 Histograms of peak inspiratory flow (PIF) in 223 asthmatic patients determined using In-Check® (Clement Clarke, Harlow, Essex, UK) through each adaptor: (a) Diskhaler®; (b) Diskus®; (c) Turbuhaler®.](image)
the conventional aerosol pMDI, because patients find
them easier to use and, furthermore, they do not contain
CFC. However, a potentially serious disadvantage is that
their efficient use is dependent on the generation of an
adequate inspiratory flow. Although the effect of PIF on
drug delivery through the DPI inhalation device is well
known, there have been few studies using Diskhaler®,
Diskus® and Turbuhaler® in Japanese people.23 Therefore,
we evaluated peak expiratory flow (PEF) using a
Mini-Wright® peak expiratory flow meter (Clement
Clarke, Harlow, Essex, UK) and PIF using an In-Check®
peak inspiratory flow meter (Clement Clarke) in 266 out-
patients; 223 patients with asthma and 43 subjects with
COPD (Table 1). A significant correlation between PEF
and PIF existed in patients with asthma and those with
COPD, but PEF was extremely low compared with PIF
in subjects with COPD (Fig. 3). This fact showed that
inspiratory airflow may be limited in patients with COPD,
but the limitation of inspiratory airflow was slight,
suggesting that COPD patients can use the DPI as well
as asthmatic patients. Next, PIF through Diskhaler®,
Diskus® or Turbuhaler® was measured at a maximal
forced inspiration using another In-check® attached to
each inhaler adaptor. Histograms of PIF for each device
adaptor in the 223 asthmatic patients are shown in
Fig. 4. For optimal lung deposition, patients with PIF
values of 60–90 L/min are recommended to use the
Diskhaler®, whereas those with PIF values of 30–90 L/
min are recommended to use the Diskus® or the
Turbuhaler®. In measuring PIF through the Diskhaler®,
28 asthmatic patients had a low PIF under 60 mL/min
and although these patients were almost all women, it
did not appear that the result was age dependent (age
range 25–76 years). It is suggested that PIF should be
measured before the use of DPI.

CONCLUSION

Newly refined morphometric and immunohisto-
chemical techniques have been used to detect asthma
inflammation in the small airways and these technol-
ogical changes have had a profound clinical impact.
Now, it is understood that the eosinophilic infiltration
occurs throughout the asthmatic lung. The contribu-
tion of small airway inflammation to deficits in pulmo-
mary function has been clarified by HRCT imaging.
Current treatment with CFC-BDP by pMDI or DPI can
suppress the inflammation in the large airways but a
little in the small airways. In contrast, new formul-
ations of fine-particle ICS, such as HFA-BDP, can
penetrate into the small airways and lung parenchyma.
Their potential to treat inflammation at the level of the
small airway may lead to significant improvements in
asthma outcome.

REFERENCES

1. Howarth P. The relevance of and site of airway inflamma-
2. Hamid Q, Song Y, Kotsimbos TC et al. Inflammation of
small airways in asthma. J. Allergy Clin. Immunol. 1997;
100: 44–51.
3. Carroll N, Elliot J, Morton A et al. The structure of large
and small airways in nonfatal and fatal asthma. Am. Rev.
receptor localized in normal and asthmatic lung. Am. J.
5. Tashkin DP. Extra-fine corticosteroid aerosols from
hydrofluoroalkane-134a metered-dose inhalers: Potential
structural analysis of peripheral airways and arteries in
sudden fatal asthma. Am. Rev. Respir. Dis. 1991; 143:
138–43.
7. Kuwano K, Bosken CH, Pare PD et al. Small airways
dimensions in asthma and in asthma and chronic obstruc-
1220–5.
8. Carroll N, Cooke C, James A. The distribution of eosino-
phil and lymphocytes in the large and small airways of
10. Hashimoto M, Tanaka H, Abe S. Angiogenesis in inner
area of the middle bronchus may correlate with airflow
11. Li X, Wilson JW. Increased vascularity of the bronchial
1997; 156: 229–33.
12. Salvato G. Quantitative and morphological analysis of
the vascular bed in bronchial biopsy specimens from
asthmatic and non-asthmatic subjects. Thorax 2001; 56:
902–6.
in severe glucocorticosteroid-dependent asthma. Eur.